{"analyses":[{"ciLowerLimit":"-0.9","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.9","estimateComment":"Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 2)","groupDescription":"Anti-HPV 6","groupIds":["OG000","OG001"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).","nonInferiorityType":"EQUIVALENCE","paramType":"Percentage Point Difference","paramValue":"0.0"},{"ciLowerLimit":"-0.4","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.7","estimateComment":"Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 6","groupIds":["OG000","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).","nonInferiorityType":"EQUIVALENCE","paramType":"Percentage Point Difference","paramValue":"0.5"},{"ciLowerLimit":"-0.4","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.7","estimateComment":"Percentage Point Difference = 9- to 15-Year-Old Females (Lot 2) minus 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 6","groupIds":["OG001","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).","nonInferiorityType":"EQUIVALENCE","paramType":"Percentage Point Difference","paramValue":"0.6"},{"ciLowerLimit":"-0.7","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.7","estimateComment":"Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 2)","groupDescription":"Anti-HPV 11","groupIds":["OG000","OG001"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).","nonInferiorityType":"EQUIVALENCE","paramType":"Percentage Point Difference","paramValue":"0.0"},{"ciLowerLimit":"-0.4","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.3","estimateComment":"Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 11","groupIds":["OG000","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).","nonInferiorityType":"EQUIVALENCE","paramType":"Percentage Point Difference","paramValue":"0.4"},{"ciLowerLimit":"-0.4","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.3","estimateComment":"Percentage Point Difference = 9- to 15-Year-Old Females (Lot 2) minus 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 11","groupIds":["OG001","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).","nonInferiorityType":"EQUIVALENCE","paramType":"Percentage Point Difference","paramValue":"0.4"},{"ciLowerLimit":"-0.7","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.7","estimateComment":"Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 2)","groupDescription":"Anti-HPV 16","groupIds":["OG000","OG001"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).","nonInferiorityType":"EQUIVALENCE","paramType":"Percentage Point Difference","paramValue":"0.0"},{"ciLowerLimit":"-0.4","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.3","estimateComment":"Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 16","groupIds":["OG000","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).","nonInferiorityType":"EQUIVALENCE","paramType":"Percentage Point Difference","paramValue":"0.4"},{"ciLowerLimit":"-0.4","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.3","estimateComment":"Percentage Point Difference = 9- to 15-Year-Old Females (Lot 2) minus 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 16","groupIds":["OG001","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).","nonInferiorityType":"EQUIVALENCE","paramType":"Percentage Point Difference","paramValue":"0.4"},{"ciLowerLimit":"-1.1","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.5","estimateComment":"Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 2)","groupDescription":"Anti-HPV 18","groupIds":["OG000","OG001"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).","nonInferiorityType":"EQUIVALENCE","paramType":"Percentage Point Difference","paramValue":"-0.2"},{"ciLowerLimit":"-0.7","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.1","estimateComment":"Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 18","groupIds":["OG000","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).","nonInferiorityType":"EQUIVALENCE","paramType":"Percentage Point Difference","paramValue":"0.2"},{"ciLowerLimit":"-0.4","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.3","estimateComment":"Percentage Point Difference = 9- to 15-Year-Old Females (Lot 2) minus 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 18","groupIds":["OG001","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).","nonInferiorityType":"EQUIVALENCE","paramType":"Percentage Point Difference","paramValue":"0.4"},{"ciLowerLimit":"-0.7","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.7","estimateComment":"Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 2)","groupDescription":"Anti-HPV 31","groupIds":["OG000","OG001"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).","nonInferiorityType":"EQUIVALENCE","paramType":"Percentage Point Difference","paramValue":"0.0"},{"ciLowerLimit":"-0.6","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.0","estimateComment":"Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 31","groupIds":["OG000","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).","nonInferiorityType":"EQUIVALENCE","paramType":"Percentage Point Difference","paramValue":"0.2"},{"ciLowerLimit":"-0.5","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.0","estimateComment":"Percentage Point Difference = 9- to 15-Year-Old Females (Lot 2) minus 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 31","groupIds":["OG001","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).","nonInferiorityType":"EQUIVALENCE","paramType":"Percentage Point Difference","paramValue":"0.2"},{"ciLowerLimit":"-0.7","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.7","estimateComment":"Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 2)","groupDescription":"Anti-HPV 33","groupIds":["OG000","OG001"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).","nonInferiorityType":"EQUIVALENCE","paramType":"Percentage Point Difference","paramValue":"0.0"},{"ciLowerLimit":"-0.4","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.3","estimateComment":"Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 33","groupIds":["OG000","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).","nonInferiorityType":"EQUIVALENCE","paramType":"Percentage Point Difference","paramValue":"0.4"},{"ciLowerLimit":"-0.4","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.3","estimateComment":"Percentage Point Difference = 9- to 15-Year-Old Females (Lot 2) minus 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 33","groupIds":["OG001","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).","nonInferiorityType":"EQUIVALENCE","paramType":"Percentage Point Difference","paramValue":"0.4"},{"ciLowerLimit":"-1.1","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.5","estimateComment":"Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 2)","groupDescription":"Anti-HPV 45","groupIds":["OG000","OG001"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).","nonInferiorityType":"EQUIVALENCE","paramType":"Percentage Point Difference","paramValue":"-0.2"},{"ciLowerLimit":"-0.7","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.1","estimateComment":"Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 45","groupIds":["OG000","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).","nonInferiorityType":"EQUIVALENCE","paramType":"Percentage Point Difference","paramValue":"0.2"},{"ciLowerLimit":"-0.4","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.3","estimateComment":"Percentage Point Difference = 9- to 15-Year-Old Females (Lot 2) minus 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 45","groupIds":["OG001","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).","nonInferiorityType":"EQUIVALENCE","paramType":"Percentage Point Difference","paramValue":"0.4"},{"ciLowerLimit":"-0.7","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.7","estimateComment":"Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 2)","groupDescription":"Anti-HPV 52","groupIds":["OG000","OG001"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).","nonInferiorityType":"EQUIVALENCE","paramType":"Percentage Point Difference","paramValue":"0.0"},{"ciLowerLimit":"-0.4","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.3","estimateComment":"Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 52","groupIds":["OG000","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).","nonInferiorityType":"EQUIVALENCE","paramType":"Percentage Point Difference","paramValue":"0.3"},{"ciLowerLimit":"-0.4","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.3","estimateComment":"Percentage Point Difference = 9- to 15-Year-Old Females (Lot 2) minus 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 52","groupIds":["OG001","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).","nonInferiorityType":"EQUIVALENCE","paramType":"Percentage Point Difference","paramValue":"0.4"},{"ciLowerLimit":"-0.7","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.7","estimateComment":"Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 2)","groupDescription":"Anti-HPV 58","groupIds":["OG000","OG001"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).","nonInferiorityType":"EQUIVALENCE","paramType":"Percentage Point Difference","paramValue":"0.0"},{"ciLowerLimit":"-0.4","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.3","estimateComment":"Percentage Point Difference = 9- to 15-Year-Old Females (Lot 1) minus 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 58","groupIds":["OG000","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).","nonInferiorityType":"EQUIVALENCE","paramType":"Percentage Point Difference","paramValue":"0.4"},{"ciLowerLimit":"-0.4","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.3","estimateComment":"Percentage Point Difference = 9- to 15-Year-Old Females (Lot 2) minus 9- to 15-Year-Old Females (Lot 3)","groupDescription":"Anti-HPV 58","groupIds":["OG001","OG002"],"nonInferiorityComment":"equivalence requires that the two-sided 95% CI for the difference in percentages between lots be entirely contained within the interval (-5, 5).","nonInferiorityType":"EQUIVALENCE","paramType":"Percentage Point Difference","paramValue":"0.4"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"98.9","upperLimit":"100.0","value":"99.8"},{"groupId":"OG001","lowerLimit":"99.0","upperLimit":"100.0","value":"99.8"},{"groupId":"OG002","lowerLimit":"98.1","upperLimit":"99.8","value":"99.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"517"},{"groupId":"OG001","value":"536"},{"groupId":"OG002","value":"544"}],"units":"Participants"}],"title":"HPV 6 cLIA ≥30 mMU/mL"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"99.3","upperLimit":"100.0","value":"100.0"},{"groupId":"OG001","lowerLimit":"99.3","upperLimit":"100.0","value":"100.0"},{"groupId":"OG002","lowerLimit":"98.7","upperLimit":"100.0","value":"99.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"517"},{"groupId":"OG001","value":"536"},{"groupId":"OG002","value":"544"}],"units":"Participants"}],"title":"HPV 11 cLIA ≥16 mMU/mL"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"99.3","upperLimit":"100.0","value":"100.0"},{"groupId":"OG001","lowerLimit":"99.3","upperLimit":"100.0","value":"100.0"},{"groupId":"OG002","lowerLimit":"98.7","upperLimit":"100.0","value":"99.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"529"},{"groupId":"OG001","value":"542"},{"groupId":"OG002","value":"556"}],"units":"Participants"}],"title":"HPV 16 cLIA ≥20 mMU/mL"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"99.0","upperLimit":"100.0","value":"99.8"},{"groupId":"OG001","lowerLimit":"99.3","upperLimit":"100.0","value":"100.0"},{"groupId":"OG002","lowerLimit":"98.7","upperLimit":"100.0","value":"99.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"531"},{"groupId":"OG001","value":"547"},{"groupId":"OG002","value":"563"}],"units":"Participants"}],"title":"HPV 18 cLIA ≥24 mMU/mL"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"99.3","upperLimit":"100.0","value":"100.0"},{"groupId":"OG001","lowerLimit":"99.3","upperLimit":"100.0","value":"100.0"},{"groupId":"OG002","lowerLimit":"99.0","upperLimit":"100.0","value":"99.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"522"},{"groupId":"OG001","value":"542"},{"groupId":"OG002","value":"553"}],"units":"Participants"}],"title":"HPV 31 cLIA ≥10 mMU/mL"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"99.3","upperLimit":"100.0","value":"100.0"},{"groupId":"OG001","lowerLimit":"99.3","upperLimit":"100.0","value":"100.0"},{"groupId":"OG002","lowerLimit":"98.7","upperLimit":"100.0","value":"99.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"534"},{"groupId":"OG001","value":"543"},{"groupId":"OG002","value":"560"}],"units":"Participants"}],"title":"HPV 33 cLIA ≥8 mMU/mL"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"99.0","upperLimit":"100.0","value":"99.8"},{"groupId":"OG001","lowerLimit":"99.3","upperLimit":"100.0","value":"100.0"},{"groupId":"OG002","lowerLimit":"98.7","upperLimit":"100.0","value":"99.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"534"},{"groupId":"OG001","value":"548"},{"groupId":"OG002","value":"565"}],"units":"Participants"}],"title":"HPV 45 cLIA ≥8 mMU/mL"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"99.3","upperLimit":"100.0","value":"100.0"},{"groupId":"OG001","lowerLimit":"99.3","upperLimit":"100.0","value":"100.0"},{"groupId":"OG002","lowerLimit":"98.7","upperLimit":"100.0","value":"99.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"533"},{"groupId":"OG001","value":"547"},{"groupId":"OG002","value":"562"}],"units":"Participants"}],"title":"HPV 52 cLIA ≥8 mMU/mL"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"99.3","upperLimit":"100.0","value":"100.0"},{"groupId":"OG001","lowerLimit":"99.3","upperLimit":"100.0","value":"100.0"},{"groupId":"OG002","lowerLimit":"98.7","upperLimit":"100.0","value":"99.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"531"},{"groupId":"OG001","value":"539"},{"groupId":"OG002","value":"560"}],"units":"Participants"}],"title":"HPV 58 cLIA ≥8 mMU/mL"}],"denoms":[{"counts":[{"groupId":"OG000","value":"535"},{"groupId":"OG001","value":"549"},{"groupId":"OG002","value":"565"}],"units":"Participants"}],"description":"Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post- vaccination 3 using cLIA. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.","dispersionType":"95% Confidence Interval","groups":[{"description":"9-valent human papillomavirus (9vHPV) L1 virus-like particle (VLP) vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 1.","id":"OG000","title":"Base Study: 9- to 15-Year-Old Females (Lot 1)"},{"description":"9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 2.","id":"OG001","title":"Base Study: 9- to 15-Year-Old Females (Lot 2)"},{"description":"9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 3.","id":"OG002","title":"Base Study: 9- to 15-Year-Old Females (Lot 3)"}],"paramType":"NUMBER","populationDescription":"9- to 15-year-old females who received 3 vaccinations from Lots 1, 2, and 3 and met following criteria for at least 1 of the 9 HPV types: no general protocol violations, received all 3 vaccinations within acceptable day ranges, seronegative at Day 1 for HPV type(s), and had a Month 7 serum sample collected within an acceptable day range","reportingStatus":"POSTED","timeFrame":"4 weeks post-vaccination 3 (Month 7)","title":"Base Study: Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine (Lot Consistency Study)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}